EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Oral MIB ‐626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID ‐19 and Acute Kidney Injury: A Randomized Controlled Trial

Karol M Pencina, David E Leaf, Rodrigo J Valderrabano, Sushrut S Waikar, Tapan S Mehta, Yili Valentine Shang, Nancy K Latham, Tejossy John, Elena Volpi, Dahlene Fusco, Yusnie Memish-Beleva, Shobana Krishnamurthy und 4 weitere

FASEB BioAdvances · 2025-08 · 7 (8)

DOI: 10.1096/fba.2025-00014 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift FASEB BioAdvances, online erschienen am 18.06.2025. Verfasst von Karol M Pencina und 15 weiteren Autor:innen. Beteiligte Einrichtung: Research Program in Men's Health: Aging and Metabolism Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Har…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nicotinamide adenine dinucleotide (NAD + ) plays an important role in the innate immune response and is depleted during SARS‐CoV‐2 infection due to increased turnover. It is unknown whether treatment with NAD + precursors can safely raise NAD + levels in patients with COVID‐19. To determine whether MIB‐626 ( β‐ nicotinamide mononucleotide), an NAD + precursor, can safely increase blood NAD + levels and attenuate acute kidney injury (AKI) and inflammation in hospitalized patients with COVID‐19, 42 adults, ≥ 18 years, hospitalized with COVID‐19 and AKI, were randomized in a 3:2 ratio to MIB‐626 1.0‐g or placebo tablets twice daily for 14 days. Circulating NAD + and its metabolites, markers of AKI, inflammation, and disease severity, were assessed. MIB‐626 treatment significantly but gradually raised blood NAD + levels to a peak between 5 to 14 days (16.0 ± 6.9, 25.5 ± 12.6, and 42.6 ± 25.6 μg/mL at baseline, days 5 and 14) and raised plasma concentrations of NAD + metabolites 1‐methylnicotinamide, N‐methyl, 2‐pyridone, 4‐carboxamide rapidly to a peak by day 3. Changes in serum creatinine, cystatin‐C, and serum markers of AKI did not differ significantly between groups. Serum CRP, IL‐6, and TNFα and indices of disease severity also did not differ between groups. MIB‐626 treatment of patients with COVID‐19 and AKI safely and substantially raised blood NAD + and plasma concentrations of NAD + metabolites. Markers of AKI, inflammation, and disease severity did not differ between groups, likely due to the slow rise in NAD + levels. Future studies should assess whether a rapid increase in NAD + by parenteral administration can attenuate disease severity and AKI. Trial Registration: ClinicalTrials.gov Identifier: NCT05038488

Schlagwörter

Stichwörter der Autor:innen

COVID‐19NAD augmentationNAD metabolismNAD precursoracute kidney injurynicotinamide mononucleotide

Autor:innen und Institutionen

  • Research Program in Men's Health: Aging and Metabolism Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA.
  • Division of Renal Medicine Brigham and Women's Hospital Boston Massachusetts USA.
  • Department of Medicine, Section of Nephrology Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.
  • Department of Family and Community Medicine University of Alabama Birmingham Alabama USA.
  • University of Texas Medical Branch Galveston Texas USA.
  • Tulane University School of Medicine New Orleans Louisiana USA.

ORCID-Profile: Shalender Bhasin

Zitieren

APA

Pencina, K. M., Leaf, D. E., Valderrabano, R. J., Waikar, S. S., Mehta, T. S., Shang, Y. V., Latham, N. K., John, T., Volpi, E., Fusco, D., Memish-Beleva, Y., Krishnamurthy, S., Lavu, S., Karmi, S., Livingston, D. J., & Bhasin, S. (2025). Oral MIB ‐626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID ‐19 and Acute Kidney Injury: A Randomized Controlled Trial. FASEB BioAdvances, 7(8). https://doi.org/10.1096/fba.2025-00014

Vancouver

Pencina KM, Leaf DE, Valderrabano RJ, Waikar SS, Mehta TS, Shang YV, et al. Oral MIB ‐626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID ‐19 and Acute Kidney Injury: A Randomized Controlled Trial. FASEB BioAdvances. 2025;7(8). doi:10.1096/fba.2025-00014

BibTeX
@article{Pencina2025,
  author = {Pencina, Karol M and Leaf, David E and Valderrabano, Rodrigo J and Waikar, Sushrut S and Mehta, Tapan S and Shang, Yili Valentine and Latham, Nancy K and John, Tejossy and Volpi, Elena and Fusco, Dahlene and Memish-Beleva, Yusnie and Krishnamurthy, Shobana and Lavu, Siva and Karmi, Salma and Livingston, David J and Bhasin, Shalender},
  title = {Oral MIB ‐626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID ‐19 and Acute Kidney Injury: A Randomized Controlled Trial},
  journal = {FASEB BioAdvances},
  year = {2025},
  volume = {7},
  number = {8},
  doi = {10.1096/fba.2025-00014}
}
Kostenlos starten →